Nektar Therapeutics (NKTR) Tops Q3 EPS by 22c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $66.84 --0%
EPS Growth %: -215.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -215.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.39, $0.22 better than the analyst estimate of $0.17. Revenue for the quarter came in at $152.9 million versus the consensus estimate of $114.62 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- William Blair Downgrades Endava PLC (ADR) (DAVA) to Underperform
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
